Results 141 to 150 of about 5,421 (159)

Sulbactam–durlobactam for Acinetobacter pneumonia

The Lancet Infectious Diseases, 2023
Ammara Mushtaq, Abhinandan Anand Raman
openaire   +1 more source

Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex

The Lancet Infectious Diseases, 2023
Giuliano S., Sbrana F., Tascini C.
openaire   +3 more sources

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii

Expert Review of Anti-infective Therapy
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against ...
Yakun, Fu, Tomefa E, Asempa, Joseph L, Kuti   +2 more
openaire   +2 more sources

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review

Infectious Disorders - Drug Targets
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan, Sajitha Venkatesan, Hadush Negash Meles, Krishnapriya Neelambaram, Pugazhenthan Thangaraju   +4 more
openaire   +2 more sources

Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply

The Lancet Infectious Diseases, 2023
Keith S, Kaye, Sarah M, McLeod, John P, O'Donnell, David, Altarac   +3 more
openaire   +2 more sources

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review

Antibiotics, 2022
Stefano di Bella, Mariagrazia Perilli, Luigi Principe   +2 more
exaly  

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021

Antimicrobial Agents and Chemotherapy, 2022
James Karlowsky, Alita Miller, Meredith Hackel   +2 more
exaly  

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies

Clinical Infectious Diseases, 2023
Alita Miller, Krisztina Papp-Wallace, Sarah McLeod   +2 more
exaly  

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

Clinical Infectious Diseases, 2023
John O'Donnell
exaly  

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii

Antimicrobial Agents and Chemotherapy, 2023
Samir Moussa, Adam Shapiro, Ramkumar Iyer   +2 more
exaly